Stunner AF system
Forecast overview
- Subagency
- FDA
- NAICS
- 334516
- Program office
- 75F401
FDA, Center for Biologics Evaluation and Research (CBER), has a requirement for an analytical system with advanced, integrated multi-attribute characterization platform to enable characterization of Adeno-Associated Virus (AAV) vectors and Lipid Nanoparticles (LNPs). The laboratory develops next-generation AAV vectors and evaluates their immunogenicity and quality attributes. A critical need is the ability to measure genome packaging efficiency (empty/full ratio), which is the most important CQA for AAV products. The instrument must simultaneously measure dynamic light scattering (DLS) for particle sizing, UV-Visible absorbance for concentration quantification, and fluorescence for encapsulation efficiency (EE%) determination - all from a single, low-volume (2 L) sample in a high-throughput plate-based format. The Unchained Labs Stunner AF system or equal system, will allow measurement of all four CQAs from a single 2 L sample in one run. The requirement also has four 1-year post-warranty service agreement options.
Related federal terms
- NAICS — North American Industry Classification System
Acquisition timeline
- Last verified on RFPCapture
- 2026-08-31
- Estimated award
- 8/2026 (agency estimate)
- Expected period of performance end
- 8/2026 (agency estimate)
Market context
- NAICS market
- NAICS 334516
Action links
Track this forecast in CaptureIQ
Source
- Source
- HHS SBCX Forecast Export
- Source file
- Forecast.csv
- Official source
- Agency forecast source
- Last verified
- 2026-08-31